 |
|
|
| |
Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants
With Hepatitis C Virus Genotypes 1 and 4 Infection:
An Integrated Analysis of Data From 11 Phase 2/3 Trials
|
| |
| |
Reported by Jules Levin
AASLD - The Liver Meeting 2017; Washington, DC; October 20-24, 2017
Lai Wei1; Hiromitsu Kumada2; Ponni V. Perumalswami3; Tawesak Tanwandee4; Wendy Cheng5; Jeong Heo6; Pin-Nan Cheng7; Peggy Hwang8; Sheng Mei Mu9; Xu Min Zhao9; Michael Robertson8; Barbara Haber8; Rohit Talwani8
1Peking University People's Hospital, Beijing, China; 2Toranomon Hospital, Tokyo, Japan; 3Icahn School of Medicine at Mount Sinai, New York, NY, USA; 4Siriraj Hospital, Bangkok, Thailand; 5Royal Perth Hospital, Perth, WA, Australia;
6College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, South Korea; 7National Cheng Kung University, Tainan, Taiwan; 8Merck & Co., Inc., Kenilworth, NJ, USA; 9Merck, Sharp & Dohme, Beijing, China
|
| |
|
|
|
|
|
